09/15/2016 BioChaperone® Combo, a co-formulation of lispro and glargine, demonstrates both prandial and basal insulin time-action profiles in a single injection in type 2 diabetes, Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
09/15/2016 “BioChaperone® Combo (BC Combo) reduces post-prandial glucose in type 1 diabetes compared to conventional lispro mix 75/25 (LMx)” (Poster 836), presented by Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
09/08/2016 Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting Icon check
09/07/2016 Adocia announces new BioChaperone program combining a basal insulin and GLP-1s Icon check
08/25/2016 Adocia announces topline results of Indian Phase 3 trial of BioChaperone PDGF for diabetic foot ulcer Icon check
07/20/2016 Adocia presents first half 2016 financial results Icon check
07/05/2016 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
06/11/2016 “A Pilot Bioequivalence (BE) Study of Ultra-Rapid Concentrated BioChaperone® Lispro (BCLIS) U200 to BCLIS U100”, (Abstract 2242-PUB), presented by Dr. Grit Anderson, 76th Scientific Sessions of the American Diabetes Association, 10-14 June 2016, New Orleans, LO (USA)
06/10/2016 “Pharmacodynamic (PD) Profile of BioChaperone® Combo (BC Combo), a New Combination of Rapid-Acting and Long-Acting Insulin, in Subjects with Type 2 Diabetes Mellitus (T2DM)” (Poster 942), presented by Dr. Simon Bruce, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)
06/08/2016 Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon Icon check
06/06/2016 Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions Icon check
06/02/2016 Adocia to Present at the Jefferies 2016 Global Healthcare Conference Icon check
05/31/2016 Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Icon check
05/13/2016 Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris Icon check
05/03/2016 Adocia strengthens its BioChaperone Combo patent portfolio Icon check
04/27/2016 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes Icon check
04/14/2016 Adocia announces first quarter 2016 results Icon check
04/11/2016 Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Icon check
04/11/2016 Adocia announces the release of its Reference Document, for the year 2015 Icon check
03/25/2016 ADOCIA confirms its eligibility for the PEA – PME Icon check
03/21/2016 Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board Icon check
03/16/2016 Annual Financial Results 2015 Icon check
03/14/2016 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Icon check
02/16/2016 ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015 Icon check
02/04/2016 Adocia to Present at the 2016 Leerink Global Healthcare Conference Icon check
01/29/2016 Adocia and Lilly initiate Phase 1b study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Icon check
01/08/2016 Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets Icon check
12/16/2015 Adocia announces its financial calendar for 2016 Icon check
12/15/2015 Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 Icon check
12/11/2015 Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100 Icon check
11/25/2015 Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes Icon check
11/19/2015 Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the “Listed Company” category for the Grand Rhône-Alpes region Icon check
11/04/2015 Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes Icon check
10/13/2015 ADOCIA Reports Third Quarter 2015 Financial Results Icon check
10/06/2015 Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy Icon check
10/05/2015 Adocia to hold an extraordinary shareholders’ meeting on November 12, 2015 in Lyon Icon check
09/30/2015 Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes Icon check
09/17/2015 ADOCIA: additional contribution to the liquidity agreement Icon check
08/27/2015 Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Icon check
07/21/2015 Adocia presents financial results for the first half of 2015 highlighting strong growth Icon check
07/10/2015 Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo
06/26/2015 Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Icon check
06/15/2015 Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices Icon check
06/05/2015 “Ultra-Rapid BioChaperone® Insulin Lispro (BC LIS): Linear Dose-Response and Faster Absorption than Insulin Lispro (LIS)” (Poster 979), presented by Dr. Grit Anderson, 75th Scientific Sessions of the American Diabetes Association, 5-9 June 2015, Boston, MA (USA)
05/28/2015 Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015 Icon check
05/26/2015 Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA) Icon check
05/04/2015 Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 Icon check
04/29/2015 Adocia is now integrated into the EnterNext Tech 40 Index Icon check
04/20/2015 Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon Icon check
04/14/2015 Adocia announces first quarter 2015 results Icon check
03/16/2015 Adocia will present its 2014 annual results and its perspectives of growth during a conference call Icon check
03/10/2015 Adocia reports a strengthened cash position and intensifies clinical development Icon check
03/05/2015 Adocia opens a subsidiary in the USA and is pleased to appoint Simon Bruce, MD and Stephen Daly Icon check
02/17/2015 ADOCIA: annual revenue and net cash position for 2014 Icon check
02/10/2015 Adocia: modification of the means allocated to the liquidity agreement Icon check
02/05/2015 Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet Icon check
01/20/2015 Adocia initiates a clinical study on the post-meal effect of ultra-rapid BioChaperone Lispro insulin formulation Icon check
01/09/2015 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
12/29/2014 ADOCIA announces its financial calendar for 2015 Icon check
12/22/2014 ADOCIA: shareholder newsletter and invitation to two conference calls today and tomorrow Icon check
Join our mailing list. Subscribe